Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 1999

View Archived Issues

Isis's new antisense compounds modulating human CD40 expression

Paladin to distribute Plan B morning-after pill in Canada

LifeTime receives FDA clearance to begin phase I/II trials of anticancer drug

Abbott signs licensing agreement with Wakunaga for two quinolone antibiotics

Takeda obtains North American marketing rights to Interneuron's stroke therapy

AVI and XTL collaborate on HBV and HCV treatments

Zoloft receives FDA approval for posttraumatic stress disorder

CV Therapeutics advances CVT-510 into phase II clinical trials

Aphton files IND for novel antigastrin therapy

Flamel Technologies and Novo Nordisk enter agreement for long-acting insulin

Natural metabolites of Et-743 with good antitumor activity identified by Pharma Mar

P&U initiates European registration process for oxazolidinone

Vyrex synthesizes new water-soluble propofol esters

Modulators of K(ATP) channels designed at Novo Nordisk particularly for endocrine disorders

Lilly's new serotonergic indole derivatives useful for CNS disorders

Potent and selective caspase 1 (ICE) inhibitors codeveloped at Warner-Lambert and BASF

Merck angiogenesis inhibitor is the subject of European phase II and U.S. phase I trials

Reversible inhibitors of methionine aminopeptidase-2 as antiangiogenic agents

ABX-CBL enters late-stage clinical development following promising results in GVHD patients

Dusa receives first approval of Levulan PDT for treatment of actinic keratoses

Clinical development of ISIS-2302 progresses steadily

Immune Network Research to proceed with phase II program for Alzheimer's treatment

New cardiovascular gene therapy product appears to be safe in patients

Theratechnologies' PDT strategy validated in study reported at ASH

Cantab options technology related to gene therapy of neurological disorders

Another phase II clinical trial begins with ImClone's C225 for new cancer indication

IB-367 rinse effectively reduces mucositis in BMT recipients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...